Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | PALB2 del |
Gene Variant Detail | |
Relevant Treatment Approaches | PARP Inhibitor (Pan) |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
PALB2 del | ovarian cancer | sensitive | AZD5305 | Preclinical - Cell culture | Actionable | In a preclinical study, AZD5305 inhibited colony formation in an ovarian cancer cell line with PALB2 deletion in culture (PMID: 35929986). | 35929986 | |
PALB2 del | uterus leiomyosarcoma | predicted - sensitive | PARP Inhibitor (Pan) | Olaparib + Temozolomide | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) and Temodar (temozolomide) combination treatment resulted in stable disease and progression-free survival lasting 381 days in a patient with advanced uterine leiomyosarcoma harboring a homozygous deletion of PALB2 (PMID: 37467452). | 37467452 |